Illumina, Inc.
Could not find a ticker for this position, may be a filing error
A maker of DNA sequencing and genetic analysis instruments, Illumina is one of the world's largest genomics technology companies, serving researchers and clinicians in noninvasive prenatal testing and cancer detection. Founded in 1998 in San Diego by a venture capitalist and a Tufts chemist, its name comes from the Latin word for 'light,' a nod to its fluorescence-based detection—and despite how it sounds, it has nothing to do with the Illuminati. Sequencing machines like the MiSeq decode genomes.
0% convertible bond due 08/15/2023
Granted 4.6K · Sold 2.05M
Granted 120.3K · Sold 1.30M
Granted 70.0K · Sold 265.9K
Granted 3.93M · Sold 4.56M
Granted 245.0K · Sold 201.0K
Granted 342.2K · Sold 81.0K
Granted 664.8K · Sold 583.0K
Granted 104.9K · Bought 19.7K
Granted 114.4K · Sold 106.3K
Granted 46.7K · Sold 23.9K
Granted 541.6K · Sold 391.2K
Granted 110.6K · Sold 45.5K
Granted 599.5K · Sold 556.9K
Granted 60.2K · Sold 57.5K
Granted 46.0K
Granted 27.3K
Granted 28.0K · Bought 6.1K
Granted 67.8K · Sold 51.1K
Granted 398.9K · Sold 313.7K
Granted 30.2K
Granted 466.2K · Sold 446.8K
Granted 30.8K
Granted 4.3K · Sold 2.3K
Granted 25.7K
Granted 65.5K · Sold 36.3K
Granted 21.7K · Sold 3.9K
Granted 14.2K · Sold 2.9K
Granted 25.1K · Sold 4.3K
Granted 190.5K · Sold 126.9K
Granted 124.3K · Sold 54.2K
Granted 17.2K
Granted 19.3K
Granted 19.9K
Granted 140.5K · Bought 3.1K · Sold 122.9K
Granted 45.3K · Bought 3.0K · Sold 30.7K
Granted 962.8K · Sold 869.8K
Granted 103.5K · Sold 53.2K
Granted 44.1K · Sold 30.5K
Granted 17.3K
Granted 23.2K · Sold 1.0K
Granted 195.3K · Sold 173.1K
Granted 14.0K · Bought 700
Granted 23.1K · Sold 4.5K
Granted 13.0K · Sold 2.0K
Granted 15.7K · Sold 2.3K
Granted 46.5K · Sold 18.9K
Granted 24.3K · Sold 7.1K
Granted 11.9K
Granted 10.1K
Granted 174.4K · Sold 155.1K
Granted 133.8K · Sold 118.8K
Granted 9.3K
Granted 8.3K
Granted 8.5K
Granted 39.0K · Sold 30.0K
Granted 28.8K · Sold 13.8K
Granted 4.8K
Granted 12.5K · Sold 6.6K
Granted 31.2K · Sold 18.0K
Granted 5.2K
Granted 4.1K
Granted 110.3K · Sold 94.5K
Granted 43.0K · Sold 40.0K
Granted 2.1K
Granted 1.8K
Granted 1.7K
Granted 5.8K · Sold 3.1K
Granted 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Meister Keith A.Director · 78 transactions | — | 15.05M | 4.6K | — | 2.05M |
| Walt David RDirector · 4182 transactions | — | 1.37Mas of Apr 2016 | 120.3K | — | 1.30M |
| Stuelpnagel John RSr VP and COO, Director · 42 transactions | — | 337.8Kas of Mar 2008 | 70.0K | — | 265.9K |
| Flatley Jay TDirector · 1122 transactions | — | 328.9Kas of May 2021 | 3.93M | — | 4.56M |
| West JohnSr. VP & GM DNA Sequencing · 345 transactions | — | 142.1Kas of Nov 2007 | 245.0K | — | 201.0K |
| deSouza Francis APresident and CEO, Director · 199 transactions | — | 121.0Kas of Mar 2023 | 342.2K | — | 81.0K |
| Orpin TristanEVP Clinical Genomics · 273 transactions | — | 118.3Kas of Nov 2016 | 664.8K | — | 583.0K |
| Thaysen JacobChief Executive Officer, Director · 21 transactions | — | 109.1K | 104.9K | 19.7K | — |
| Rastetter William HDirector · 58 transactions | — | 95.2Kas of Jan 2016 | 114.4K | — | 106.3K |
| Tousi Susan HSVP, Chief Commercial Officer · 65 transactions | — | 89.3Kas of Nov 2023 | 46.7K | — | 23.9K |
| Ronaghi MostafaSVP, Entrepreneurial Devlopmt · 238 transactions | — | 80.2Kas of Dec 2020 | 541.6K | — | 391.2K |
| Bianchi Paul LSr. VP, Human Resources · 36 transactions | — | 65.7Kas of Apr 2016 | 110.6K | — | 45.5K |
| Cabou ChristianSr VP & General Counsel · 154 transactions | — | 60.5Kas of Apr 2013 | 599.5K | — | 556.9K |
| Lewis Mark LSr VP & General Manager · 16 transactions | — | 49.8Kas of Nov 2013 | 60.2K | — | 57.5K |
| Cunningham EverettSVP, Chief Commercial Officer · 3 transactions | — | 46.6Kas of Jul 2025 | 46.0K | — | — |
| Barnard StevenSVP, Chief Technology Officer · 15 transactions | — | 41.3K | 27.3K | — | — |
| Dhingra AnkurSVP, Chief Financial Officer · 4 transactions | — | 34.3K | 28.0K | 6.1K | — |
| Posard Matthew L.Sr VP & General Manager · 27 transactions | — | 33.7Kas of May 2013 | 67.8K | — | 51.1K |
| Naclerio NicholasSr VP, Corporate Development · 158 transactions | — | 30.0Kas of Mar 2016 | 398.9K | — | 313.7K |
| Pegels Kevin CarlChief of Global Operations · 20 transactions | — | 29.0K | 30.2K | — | — |
| Heath GregorySr VP & General Manager · 95 transactions | — | 26.7Kas of Dec 2013 | 466.2K | — | 446.8K |
| Goswami JoydeepSVP, Chief Financial Officer · 18 transactions | — | 24.5Kas of Mar 2024 | 30.8K | — | — |
| Klausner RichardSr VP, Chief Medical Officer · 10 transactions | — | 22.8Kas of Jan 2016 | 4.3K | — | 2.3K |
| Schiller Philip WDirector · 14 transactions | — | 22.2K | 25.7K | — | — |
| Epstein Robert SDirector · 76 transactions | — | 22.1Kas of May 2025 | 65.5K | — | 36.3K |
| Leckman PatriciaSVP, Chief People Officer · 20 transactions | — | 21.4K | 21.7K | — | 3.9K |
| Davies Scott MChief Legal Officer · 14 transactions | — | 21.0K | 14.2K | — | 2.9K |
| Arnold FrancesDirector · 18 transactions | — | 20.9Kas of May 2025 | 25.1K | — | 4.3K |
| Stapley MarcEVP Strategy & Corp Developmt · 201 transactions | — | 20.9Kas of Feb 2019 | 190.5K | — | 126.9K |
| Dadswell CharlesSVP, General Counsel · 135 transactions | — | 20.6Kas of Sep 2024 | 124.3K | — | 54.2K |
| Siegel Susan EDirector · 11 transactions | — | 20.5K | 17.2K | — | — |
| Rollins CarissaSVP, Chief Information Officer · 10 transactions | — | 18.4Kas of Apr 2025 | 19.3K | — | — |
| Reeves Kathryne GambrellSVP, Chief Marketing Officer · 13 transactions | — | 18.0Kas of Mar 2024 | 19.9K | — | — |
| Bowman A BlaineDirector · 187 transactions | — | 17.7Kas of May 2018 | 140.5K | 3.1K | 122.9K |
| Moeller GeraldDirector · 51 transactions | — | 17.6Kas of Mar 2015 | 45.3K | 3.0K | 30.7K |
| Henry Christian OEVP & Chief Commercial Officer · 513 transactions | — | 17.5Kas of Jan 2017 | 962.8K | — | 869.8K |
| Ostadan OmeadSVP Mktg, Prod & Strat Plan · 71 transactions | — | 17.2Kas of May 2020 | 103.5K | — | 53.2K |
| Van Oene MarkSVP Chief Commercial Officer · 62 transactions | — | 16.6Kas of Nov 2020 | 44.1K | — | 30.5K |
| Guthart Gary SDirector · 11 transactions | — | 16.4Kas of May 2025 | 17.3K | — | — |
| Dorsa CarolineDirector · 21 transactions | — | 15.8K | 23.2K | — | 1.0K |
| Bradbury DanielDirector · 305 transactions | — | 15.3Kas of May 2017 | 195.3K | — | 173.1K |
| Gottlieb ScottDirector · 14 transactions | — | 14.8K | 14.0K | 700 | — |
| Febbo Phillip G.SVP Chief Medical Officer · 26 transactions | — | 14.8Kas of Mar 2023 | 23.1K | — | 4.5K |
| Ericksen Scott DVP, Chief Accounting Officer · 15 transactions | — | 14.4K | 13.0K | — | 2.0K |
| Wedel Christensen JakobSVP, Strategy/Corp Development · 13 transactions | — | 14.0K | 15.7K | — | 2.3K |
| Aravanis AlexanderSVP, Chief Technology Officer · 36 transactions | — | 12.6Kas of Jul 2023 | 46.5K | — | 18.9K |
| Samad SamSVP and CFO · 24 transactions | — | 11.3Kas of Mar 2022 | 24.3K | — | 7.1K |
| Ullem Scott B.Director · 14 transactions | — | 10.9K | 11.9K | — | — |
| Thompson John WendellDirector · 6 transactions | — | 10.2Kas of May 2022 | 10.1K | — | — |
| Eastham KarinDirector · 121 transactions | — | 10.0Kas of May 2019 | 174.4K | — | 155.1K |
| Bouchard MichelChief Accounting Officer · 140 transactions | — | 9.5Kas of Nov 2017 | 133.8K | — | 118.8K |
| Frank John EdwardChief Public Affairs Officer · 3 transactions | — | 9.2Kas of May 2023 | 9.3K | — | — |
| Huber JeffDirector · 6 transactions | — | 8.7Kas of Dec 2015 | 8.3K | — | — |
| Richo AnnaDirector · 3 transactions | — | 8.5K | 8.5K | — | — |
| Grint Paul CDirector · 19 transactions | — | 8.4Kas of Jan 2013 | 39.0K | — | 30.0K |
| Hoyt Aimee LSVP, Chief People Officer · 46 transactions | — | 8.3Kas of Nov 2023 | 28.8K | — | 13.8K |
| Hampton Malcolm GarretSVP Clinical Genomics Group · 7 transactions | — | 6.6Kas of Jan 2020 | 4.8K | — | — |
| McComb JoelSr VP & General Manager · 4 transactions | — | 6.6Kas of Jan 2010 | 12.5K | — | 6.6K |
| Ragusa Robert PSVP, Global Quality & Ops · 37 transactions | — | 6.5Kas of Feb 2021 | 31.2K | — | 18.0K |
| Samad Samer AbdulSr. VP and CFO · 5 transactions | — | 4.8Kas of Dec 2018 | 5.2K | — | — |
| Macmillan Stephen PDirector · 2 transactions | — | 4.1Kas of May 2024 | 4.1K | — | — |
| Whitfield Roy ADirector · 74 transactions | — | 2.9Kas of Aug 2016 | 110.3K | — | 94.5K |
| Cabral Paulette DVice President Human Resources · 1 transaction | — | 2.4Kas of Jan 2006 | — | — | — |
| Goldstein JackDirector · 10 transactions | — | 2.4Kas of May 2010 | 43.0K | — | 40.0K |
| King David PDirector · 1 transaction | — | 2.1K | 2.1K | — | — |
| Torres JoseVP, Chief Accounting Officer · 3 transactions | — | 1.7Kas of May 2022 | 1.8K | — | — |
| Skovronsky DanielDirector · 1 transaction | — | 1.7K | 1.7K | — | — |
| McGinnis Karen KVP, Chief Accounting Officer · 19 transactions | — | 1.5Kas of Feb 2021 | 5.8K | — | 3.1K |
| Teno AndrewDirector · 1 transaction | — | 0as of May 2023 | 1.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -13.04M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.